See more : La Rosa Holding Corp. Common Stock (LRHC) Income Statement Analysis – Financial Results
Complete financial analysis of Craneware plc (CRWRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Craneware plc, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- HG Technologies Co., Ltd. (300847.SZ) Income Statement Analysis – Financial Results
- Xilam Animation (0GJS.L) Income Statement Analysis – Financial Results
- Live Nation Entertainment, Inc. (0JVD.L) Income Statement Analysis – Financial Results
- Ji’an Mankun Technology Co., Ltd. (301132.SZ) Income Statement Analysis – Financial Results
- VGP NV (VGPBF) Income Statement Analysis – Financial Results
Craneware plc (CRWRF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.thecranewaregroup.com
About Craneware plc
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors. It also offers InSight Denials to analyze, track, trend, and report on denial data; Trisus Healthcare Intelligence, a solution that provides insights into resource consumption on the patient level; Trisus Medication Analytic solutions; and Trisus supplies assistant solutions. In addition, the company provides Sentinel, a drug tracking solution; Sentrex, a SaaS-based solution that helps covered entities expand medication access; Sentrex 330; Referral Verification System; and Sentry Core, a solution that simplifies the complexities of pharmacy procurement, utilization, and compliances. Further, it offers appeal and professional services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 189.27M | 183.64M | 151.59M | 77.61M | 70.16M | 70.21M | 65.81M | 59.21M | 44.98M | 44.82M | 42.57M | 41.45M |
Cost of Revenue | 27.07M | 60.93M | 48.15M | 10.90M | 9.01M | 7.79M | 5.56M | 4.79M | 3.84M | 2.42M | 1.94M | 2.07M |
Gross Profit | 162.20M | 122.71M | 103.44M | 66.71M | 61.15M | 62.42M | 60.25M | 54.42M | 41.14M | 42.40M | 40.63M | 39.38M |
Gross Profit Ratio | 85.70% | 66.82% | 68.24% | 85.95% | 87.16% | 88.90% | 91.56% | 91.91% | 91.46% | 94.60% | 95.44% | 95.00% |
Research & Development | 0.00 | 37.57M | 34.43M | 14.94M | 12.04M | 10.23M | 12.93M | 9.33M | 6.92M | 7.29M | 7.34M | 7.32M |
General & Administrative | 0.00 | 0.00 | 20.38M | 9.30M | 9.98M | 8.72M | 8.74M | 9.22M | 6.34M | 5.22M | 4.59M | 4.43M |
Selling & Marketing | 0.00 | 0.00 | 15.27M | 6.62M | 7.21M | 23.81M | 20.24M | 18.01M | 16.92M | 15.90M | 15.94M | 15.56M |
SG&A | 0.00 | 64.95M | 50.98M | 31.50M | 30.26M | 33.27M | 29.07M | 28.19M | 21.22M | 21.36M | 20.74M | 20.17M |
Other Expenses | 141.35M | 633.18K | 504.56K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 141.35M | 101.88M | 84.91M | 46.44M | 42.30M | 43.50M | 42.00M | 37.52M | 28.14M | 29.98M | 29.41M | 28.88M |
Cost & Expenses | 169.53M | 162.81M | 133.06M | 57.34M | 51.31M | 51.29M | 47.56M | 42.31M | 31.98M | 32.41M | 31.35M | 30.95M |
Interest Income | 1.14M | 225.83K | 915.73 | 1.03K | 188.43K | 312.71K | 236.48K | 264.31K | 101.07K | 84.00K | 66.00K | 103.00K |
Interest Expense | 5.13M | 6.71M | 4.61M | 78.04K | 92.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 33.38M | 33.94M | 26.93M | 5.38M | 4.58M | 3.47M | 2.21M | 1.12M | 1.12M | 797.00K | 905.00K | 950.00K |
EBITDA | 54.26M | 54.46M | 43.53M | 18.98M | 23.61M | 21.49M | 19.50M | 17.31M | 15.18M | 13.37M | 12.18M | 11.55M |
EBITDA Ratio | 28.67% | 29.82% | 29.99% | 33.05% | 33.39% | 31.89% | 31.10% | 30.44% | 31.41% | 29.82% | 28.60% | 27.87% |
Operating Income | 19.73M | 20.83M | 18.53M | 20.27M | 18.85M | 18.92M | 18.25M | 16.90M | 13.01M | 12.57M | 11.27M | 10.60M |
Operating Income Ratio | 10.43% | 11.34% | 12.23% | 26.11% | 26.87% | 26.95% | 27.74% | 28.55% | 28.91% | 28.05% | 26.47% | 25.58% |
Total Other Income/Expenses | -3.99M | -5.42M | -5.03M | -7.10M | -261.40K | -905.69K | -113.93K | 393.40K | -1.85M | -73.00K | 66.00K | 1.00K |
Income Before Tax | 15.75M | 13.81M | 12.00M | 13.52M | 18.94M | 18.02M | 18.58M | 17.30M | 12.56M | 12.50M | 11.29M | 10.60M |
Income Before Tax Ratio | 8.32% | 7.52% | 7.91% | 17.42% | 27.00% | 25.66% | 28.23% | 29.21% | 27.93% | 27.88% | 26.52% | 25.58% |
Income Tax Expense | 4.04M | 4.07M | 3.38M | 266.98K | 2.42M | 3.28M | 3.08M | 3.44M | 3.02M | 3.11M | 2.68M | 2.31M |
Net Income | 11.70M | 9.23M | 9.41M | 12.91M | 16.84M | 14.74M | 15.50M | 13.86M | 9.54M | 9.39M | 8.61M | 8.30M |
Net Income Ratio | 6.18% | 5.03% | 6.21% | 16.63% | 24.00% | 20.99% | 23.55% | 23.40% | 21.22% | 20.95% | 20.22% | 20.01% |
EPS | 0.33 | 0.28 | 0.25 | 0.49 | 0.62 | 0.55 | 0.58 | 0.51 | 0.36 | 0.35 | 0.32 | 0.31 |
EPS Diluted | 0.33 | 0.27 | 0.24 | 0.49 | 0.61 | 0.54 | 0.57 | 0.50 | 0.35 | 0.35 | 0.32 | 0.31 |
Weighted Avg Shares Out | 34.96M | 35.15M | 35.11M | 26.81M | 26.80M | 26.69M | 26.79M | 26.93M | 26.84M | 26.98M | 27.16M | 27.11M |
Weighted Avg Shares Out (Dil) | 35.29M | 35.44M | 35.48M | 27.19M | 27.20M | 27.25M | 27.28M | 27.52M | 27.18M | 27.00M | 27.17M | 27.07M |
Source: https://incomestatements.info
Category: Stock Reports